How to manage HBeAg-negative chronic HBV infection with normal alanine aminotransferase levels in clinical practice?

European Journal of Internal Medicine

Volumn 24, Issue 2, 2013, Pages 100-103

  Puoti, Claudio ^a  

^a Marino Hospital Rome   (Italy)

Author keywords

Alanine aminotransferase; Biopsy; Hepatitis B virus; Interferon; Normal; Nucleos(t)ide analogues

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

ANOREXIA; BODY WEIGHT; BONE MARROW SUPPRESSION; CHILL; CLINICAL PRACTICE; DISEASE TRANSMISSION; DRUG FEVER; DRUG INDUCED HEADACHE; ENDOSCOPY; FATIGUE; FOLLOW UP; HAIR LOSS; HEARTBURN; HEPATITIS B; HUMAN; LIFESTYLE; LIVER BIOPSY; LIVER CIRRHOSIS; MALAISE; MYALGIA; PRACTICE GUIDELINE; REVIEW; SEXUAL BEHAVIOR; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VACCINATION;

ALANINE TRANSAMINASE; DISEASE MANAGEMENT; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 84873713556     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2012.10.013     Document Type: Review

References (35)

1. A.S.F. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
2. D. Lavanchy Hepatitis B, virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 2004 97 107
3. E. Villa, T. Barchi, I. Ferretti, A. Grisendi, M. De Palma, and S. Bellentani Susceptibility of chronic symptomless HBsAg carriers to ethanol induced hepatic damage Lancet 2 1982 1243 1245
4. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
5. G. Fattovich Natural history and prognosis of hepatitis B Semin Liver Dis 23 2003 47 58
6. B.J. McMahon The natural history of chronic hepatitis B virus infection Semin Liver Dis 24 2004 17 21
7. G. Fattovich, T. Stroffolini, I. Zagni, and F. Donato Hepatocellular carcinoma in cirrhosis: incidence and risk factors Gastroenterology 127 2004 S35 S50
8. G.V. Papatheodoridis, S. Manolakopoulos, Y.-F. Liaw, and A. Lok Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review J Hepatol 57 2012 196 202
9. M. Martinot-Peignoux, N. Boyer, M. Colombat, R. Akremi, B.-N. Pham, and S. Ollivier Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers J Hepatol 36 2002 543 548
10. Y.C. Chen, S.F. Huang, C.M. Chu, and Y.F. Liaw Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion J Viral Hepat 19 2012 138 146
11. G.V. Papatheodoridis, N. Chrysanthos, E. Hadziyannis, E. Cholongitas, and E.K. Manesis Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection J Viral Hepat 15 2008 434 441
12. K. Ikeda, Y. Arase, S. Saitoh, M. Kobayashi, T. Someya, and T. Hosaka Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase Am J Med 119 2006 977 985
13. J.H. Hoofnagle, E. Doo, T.J. Liang, R. Fleischer, and A.S. Lok Management of hepatitis B: summary of a clinical research workshop Hepatology 45 2007 1056 1075
14. A.S. Lok, and B.J. McMahon Chronic hepatitis B Hepatology 45 2007 507 539
15. M. Lai, B.J. Hyatt, I. Nasser, M. Curry, and N.H. Afdhal The clinical significance of persistently normal ALT in chronic hepatitis B infection J Hepatol 47 2007 760 767
16. D.I. Tai, S.M. Lin, I.S. Sheen, C.M. Chu, D.Y. Lin, and Y.F. Liaw Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time Hepatology 49 2009 1859 1867
17. L. Castera, P.H. Bernard, B.B. Le, J. Foucher, P. Trimoulet, and W. Merrouche Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers Aliment Pharmacol Ther 33 2011 455 465
18. S.J. Hadziyannis, and G.V. Papatheodoridis Hepatitis B e antigen negative chronic hepatitis B - natural history and treatment Semin Liver Dis 26 2006 130 141
19. S.J. Hadziyannis, and D. Vassilopoulos Hepatitis B e antigen-negative chronic hepatitis B Hepatology 34 2001 617 624
20. J.J. Feld, M. Ayers, D. El-Ashry, T. Mazzulli, R. Tellier, and E.J. Heathcote Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B Hepatology 46 2007 1057 1070
21. C. Puoti, A. Stati, and A. Magrini Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal ALT levels Liver 19 1999 104 109
22. C. Puoti, R. Guarisco, L. Bellis, O. Dell Unto, L. Spilabotti, and O. Mitidieri Costanza HCV carriers with normal alanine aminotransferase levels: healthy people or true patients? Dealing with an everyday clinical problem Eur J Intern Med 21 2010 57 61
23. G. Zacharakis, J. Koskinas, S. Kotsiou, F. Tzara, N. Vafeiadis, and M. Papoutselis The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg-negative hepatitis B infection: association with liver disease progression. A prospective cohort study J Hepatol 49 2008 884 891
24. G. Raimondo, J.P. Allain, M.R. Brunetto, M.A. Buendia, D.S. Chen, and M. Colombo Statements from the Taormina expert meeting on occult hepatitis B virus infection J Hepatol 49 2008 652 657
25. G. Carosi, M. Rizzetto, A. Alberti, G. Cariti, M. Colombo, and A. Craxì Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop Dig Liver Dis 43 2011 259 265
26. G.K. Lau, T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, and G. Cooksley Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682 2695
27. P. Marcellin, G.K. Lau, F. Bonino, P. Farci, S. Hadziyannis, and R. Jin Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206 1217
28. P. Marcellin, F. Bonino, G.K. Lau, P. Farci, C. Yurdaydin, and T. Piratvisuth Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a Gastroenterology 136 2009 2169 2179
29. A. Bartholomeusz, and S.A. Locarnini Antiviral drug resistance: clinical consequences and molecular aspects Semin Liver Dis 26 2006 162 170
30. F. Zoulim, and S. Locarnini Hepatitis B virus resistance to nucleos(t)ide analogues Gastroenterology 137 2009 1593 1608
31. M.F. Yuen, W.K. Seto, J. Fung, D.K. Wong, J.C. Yuen, and C.L. Lai Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety Am J Gastroenterol 106 2011 1264 1271
32. E.J. Heathcote, P. Marcellin, M. Buti, E. Gane, R.A. de Man, and Z. Krastev Three year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 2011 132 143
33. F. Bonino, P. Marcellin, G.K. Lau, S. Hadziyannis, R. Jin, and T. Piratvisuth Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B Gut 56 2007 699 705
34. V. Rijckborst, B.E. Hansen, Y. Cakaloglu, P. Ferenci, F. Tabak, and M. Akdogan Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels Hepatology 52 2010 454 461
35. V. Rijckborst, B.E. Hansen, P. Ferenci, M.R. Brunetto, F. Tabak, and Y. Cakaloglu Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a J Hepatol 56 2012 1006 1011